Dopamine D1 receptors in Parkinson’s disease and striatonigral degeneration: a positron emission tomography study

H Shinotoh, O Inoue, K Hirayama, A Aotsuka, M Asahina, T Suhara, T Yamazaki, Y Tateno

Abstract

Striatal dopamine D1 receptors were investigated in 11 patients with Parkinson’s disease (PD), five patients with striatonigral degeneration (SND) and six age-matched controls by positron emission tomography and carbon-11 labelled SCH23390. The SND patients showed mean 12%, 21%, and 31% declines in the ratios of radioactivity in the caudate, anterior putamen, and posterior putamen compared with that in the occipital cortex. These ratios were not significantly altered in the PD patients. The results may explain the different therapeutic responses to levodopa between SND and PD patients, and this technique might prove useful for their differentiation.

(J Neurol Neurosurg Psychiatry 1993;56:467–472)

Dopamine receptors were initially divided into D1 and D2 receptors. The D1 receptors stimulate the dopamine dependent adenylate cyclase system, whereas the D2 receptors are independent of adenylate cyclase or inhibit adenylate cyclase. The influence of D1 receptors in Parkinson’s disease (PD) has been repeatedly investigated in vitro but there is no consensus on the type of alteration in striatal D1 receptors. Striatal D1 receptors in PD have been reported to be either unchanged or upregulated. Positron emission tomography (PET) provides a unique opportunity to assess neuroreceptors in vivo in humans, but there are few investigations to date on the status of striatal D1 receptors in patients with PD using PET.

Striatonigral degeneration (SND) presents Parkinsonian symptoms; the incidence of SND has been estimated as between 4 and 8% of Parkinsonian patients. Patients with SND usually fail to respond to levodopa therapy, whereas most patients with PD respond well to it. This poor response or lack of response in SND might be attributed to a loss of striatal dopamine receptors but there have been few studies which report the status of dopamine receptors either in vitro or in vivo.

We investigated 11 patients with PD, five patients with SND and six age-matched controls, using PET with carbon-11 labelled SCH23390.

Materials and methods

PATIENTS

The patients were clinically assessed and details are given in Table 1. Eleven patients with PD (patients 1–11), including two patients (patients 3 and 9) with young onset PD, were investigated. All PD patients except two (patients 9 and 10) presented typical Parkinsonian rest tremor in addition to akinesis and rigidity syndrome. All of the treated PD patients (patients 6–11) responded well to levodopa. Patient 9 had been treated for five years with levodopa and presented levodopa induced dyskinesia (right foot dystonia). The untreated PD patients (patients 1–5) received levodopa after the PET study and showed a good response to the therapy. Brain CT scans of all PD patients showed no abnormal findings except mild cortical atrophy in three patients. The clinical features of all PD patients met the research diagnostic criteria for Parkinson’s disease.

Five patients (patients 12–16) were diagnosed as SND based on the following findings: (1) the predominance of rigidity and akinesia with no or minimal tremor at rest; (2) no or poor response to levodopa therapy; (3) rapidly progressive disability compared with PD patients, and (4) mild to moderate cerebellar atrophy on CT scan and MRI (except in one patient, no 12). In addition to the above features, two showed slight cerebellar ataxia, two had positive Babinski sign, and four had impairment of autonomic function. Since the initial and primary finding was Parkinsonian syndrome, the specific diagnosis of SND was made rather than that of multiple system atrophies (MSA) which encompass SND, Shy-Drager syndrome, and olivopontocerebellar atrophy.

Administration of all anti-Parkinsonian drugs was discontinued at least 48 hours before the PET study. Locomotor disability was assessed based on the Hoehn and Yahr stage at the time of the PET study. Six healthy, age-matched subjects (three men and three women; mean age (SD) 65 (6) years, ranging from 56 to 73 years) served as controls. None of them showed neurological abnormalities, and they were not taking any medication at the time of the PET study. These studies were approved by the Inquiry Council of Medical and Research Morals on Medical Uses of Short-lived and Positron Radioisotopes of the National Institute of Radiological Sciences (NIRS), Japan.
Informed written consent was obtained from all the subjects.

MRI
All the patients except four PD patients underwent MRI with a Philips 1-5 tesla Gyroscan using SE pulse sequence (TR/TE: 2500/40, 80 milliseconds) at NIRS. Fourteen 5 mm thick sections with a scan plane orientation of 100 degrees positive to the axis of the brainstem (roughly parallel with the orbitomeatal line) and a 0.5 mm interval were analysed. The width of the pars compacata signal with an echo time of 40 milliseconds was measured according to the method of Dugid et al.23 and the average width of the right and left pars compacata signal was calculated. The width of the pars compacata signals of 10 healthy volunteers (six men and four women, ranging in age 40 years to 72 years) were used as the control values.

PET
The PET study was performed at NIRS. [11C]SCH23390 was prepared by N-alkylation of SCH24518 with carbon-11 labelled methylidide by analogy with the preparation of [11C]Ro15–1788.24 The total synthesis time was 35 to 40 minutes with a radiochemical purity of more than 99%, and the specific activity ranged from 13-4 to 57-5 GBq/µl at the time of injection.

A five ring, high resolution PET system was used to follow the radioactivity in nine sections of the brain covering an axial distance of 76 mm with an axial full width half maximum resolution of 5.7 mm and an inplane resolution of 3.5 mm times 3.5 mm (Hamamatsu Photonics, KK, Japan).25 The subjects were carefully positioned by using crossed laser beams, and nine sections (13, 21, 29, 37, 45, 53, 61, 69, and 77 mm above and parallel to the orbitomeatal plane) were scanned. Correction for tissue attenuation of 511 keV γ radiation was measured with an external 46Ge ring.

A mean dose of 629 pmol/kg [range from 290 to 1000 pmol/kg (450 to 945 MBq)] of [11C]SCH23390 in 2 to 5 ml of normal saline solution was infused intravenously for 30 seconds in each subject. Scanning began between 20 and 30 seconds following the start of the injection when PET first detected the radioactivity. Serial 2 minute scans were performed during the initial 10 minutes and then serial 5 minute scans were performed during the subsequent 50 minutes, yielding 15 frames over the 60 minutes period.

Circular regions of interest (ROIs) were placed on an integrated image representing the activity collected from 0 to 60 minutes following [11C]SCH23390 injection. Two sections optimum for striatum were selected and ROIs were defined in a standard arrangement: one circular ROI with a diameter of 8

---

Table 1  Clinical features of patients with Parkinson’s disease (PD), and striatoutilarg degeneration (SND)

<table>
<thead>
<tr>
<th>Patient No</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
<th>16</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age/sex (year)</td>
<td>56/M</td>
<td>62/F</td>
<td>50/M</td>
<td>56/F</td>
<td>67</td>
<td>7</td>
<td>8</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
</tr>
<tr>
<td>Duration of illness (year)</td>
<td>6 mo</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>3</td>
<td>10</td>
<td>5</td>
<td>6 mo</td>
<td>2</td>
<td>4</td>
<td>5</td>
<td>5</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Initial symptom</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rigidity</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Akinesia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td></td>
</tr>
<tr>
<td>Urinary hypo</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Gait</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Tremor</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Clustering</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Writing</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Asymmetry at onset</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Asymmetry of signs</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Dominant side</td>
<td>R</td>
<td>L</td>
<td>L</td>
<td>L</td>
<td>R</td>
<td>L</td>
<td>R</td>
<td>L</td>
<td>R</td>
<td>R</td>
<td>L</td>
<td>L</td>
<td>L</td>
<td>L</td>
<td>L</td>
<td>L</td>
</tr>
<tr>
<td>Clinical signs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rigidity</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Akinesia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Urinary hypo</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Gait</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Tremor</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Clustering</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Writing</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Asymmetry at onset</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Asymmetry of signs</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Dominant side</td>
<td>R</td>
<td>L</td>
<td>L</td>
<td>L</td>
<td>R</td>
<td>L</td>
<td>R</td>
<td>L</td>
<td>R</td>
<td>R</td>
<td>L</td>
<td>L</td>
<td>L</td>
<td>L</td>
<td>L</td>
<td>L</td>
</tr>
<tr>
<td>Clinical signs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rigidity</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Akinesia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Urinary hypo</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Gait</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Tremor</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Clustering</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Writing</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
<td>NE</td>
</tr>
</tbody>
</table>

---

Figure 1  A plot of caudate/occipital cortex [11C]SCH23390 uptake ratio against mid scan time for a patient with Parkinson’s disease (woman aged 62). The ratio is approached for the [11C]SCH23390 injection. The average value of the ratio during the time interval of 30 to 60 minutes was used as an index of D1 receptor binding.
pixels (12-0 mm) was placed on the head of the caudate, and two circular ROI with a
diameter of 8 pixels were aligned along the
axis of the putamen for each hemisphere. One circular ROI with a diameter of 14 pixels
(21-0 mm) was placed over the occipital cor-
text of each hemisphere. Two sections optimum
for cerebellum were selected and one
circular ROI with a diameter of 14 pixels was
placed over each cerebellar hemisphere in
each section. ROIs were determined by
inspection with reference to the correspond-
ing brain CT scan and the brain atlas of
Matsui and Hirano.26 Average values for each
anatomical structure over the two optimum
sections were then calculated from the indi-
vidual ROI data.

A regional time activity curve was obtained
following correction for carbon-11 decay, and
the ratios of radioactivity in each striatal ROI
to that in the cerebellum (St/Cbl) and to that in
the occipital cortex (St/Ctx) were calculat-
ed. Since both the St/Cbl ratio and the St/Ctx
ratio reached a plateau 30 minutes after the
injection, suggesting that a pseudoequilibri-
um of D1 receptor binding was achieved, the
average values of the St/Cbl ratio and St/Ctx
ratio during the time interval of 30 to 60 min-
utes were used as indices of D1 receptor
binding (fig 1). The St/Ctx ratios were 11%
to 19% lower than the St/Cbl ratios in the
controls owing to the small amount of specif-
ic binding of \[^{11}\mathrm{C}\]SCH23390 in the cerebral
cortex.27

The cerebellum has virtually no dopamine
D1 receptors27 and is an ideal tissue to esti-
mate non-specific striatal tracer binding.
However, in this study there was mild to
moderate cerebellar atrophy in SND patients,
which might be considered to affect the
uptake of carbon-11 in the cerebellum of
those patients. Therefore, only the St/Ctx
ratios are shown below.

The St/Ctx ratios for the patients with
SND were compared with those from
patients with PD and normal controls by
using Mann-Whitney U tests, with the
Bonferroni correction for multiple compari-
sion.28 A correlation analysis of the duration of
illness, the locomotor disability, and the
abnormal MRI findings with the St/Ctx ratios
was performed.

Results

MRI

The measured width of the pars compac-
ta signal in all PD and SND patients was nar-
rower than 1 SD of the mean control values
(\( n = 10 \), mean (SD) 4.3 (0.6) mm) (table 1).29 T2-weighted MRI showed an abnormal
prominence of signal hypointensity in the
bilateral putamen in two of the five SND
patients (fig 2), but no obvious atrophy of the
striatum was noted in the SND patients. No
abnormal findings were noted in the putamen
of the PD patients.

PET

There was rather uniform distribution of car-
bon-11 in the caudate head, and putamen in
the controls and PD patients following
\[^{11}\mathrm{C}\]SCH23390 injection (fig 3).

The mean ratios of radioactivity of the cau-
date, anterior putamen, and posterior puta-
tmen to that of the occipital cortex in the PD
group were similar to the control values (figs
4, 5, table 2). No significant left/right differ-
ce was noted in the PD, when carbon-11
accumulation in the striatum contralateral to
the predominant side of the Parkinsonian
symptoms was compared with that in the
opposite striatum. The St/Ctx ratios between
the untreated (patients 1–5) and the treated
PD patients (patients 6—11) were similar (fig 4). In the PD patients there was no significant correlation between these ratios and the locomotor disability, between the ratios and the duration of illness, or between the ratios and the measured width of pars compacta by MRI.

In contrast to the PD patients, in the SND patients a significant decrease in carbon-11 accumulation in the striatum, especially in the dorsal posterior putamen was noted (fig 3). The St/Ctx ratios in the SND group were lower than those in the control and PD groups. These ratios were the lowest in the posterior putamen among the three regions in the striatum of the SND patients (figs 4, 5, table 2). There was a trend for the ratios in the posterior putamen to decrease in the SND patients with the advance in locomotor disability. In the SND patients there was no correlation between the St/Ctx ratios and the measured width of pars compacta or between the ratios and the abnormal hypointensity of putamen in MRI.

The analysis of the St/Cbl ratios produced similar results to that of the St/Ctx ratios (data not shown).

**Discussion**

The present PET findings suggest that there is no significant alteration of striatal D1 receptor binding in the PD patients. No significant difference was found between the St/Ctx ratios in the untreated and the treated PD patients. These results indicated that striatal D1 receptor binding is not upregulated in the untreated PD, and it is not downregulated by the treatment with anti-Parkinsonian drugs including levodopa in the PD patients.

In vitro studies, some reports have proposed the upregulation of D1 receptors in PD, especially in untreated PD, while other reports claim that there is no alteration of D1 receptors in PD. Rinne and co-workers investigated D1 receptors in five untreated, early PD patients using PET and [11C]SCH23390. They found no left/right difference in D1 receptor binding in spite of asymmetrical symptoms in these patients, suggesting that there is no denervation hypersensitivity of D1 receptors in these patients. Likewise, in the present study there was no significant left/right difference in the PD. Striatal D1 receptors appear to be unaffected by the loss of nigrostriatal neurons. Recent animal studies have demonstrated that striatal D1 receptors are not altered by basal ganglia dopamine depletion.

In contrast to PD patients, there was a marked loss of striatal D1 receptor binding in the SND patients. The five SND patients showed mean 12%, 21%, and 31% declines in the ratios of radioactivity in the caudate, anterior putamen, and posterior putamen to that in the occipital cortex. We believe this is the first report of the status of striatal D1 receptors in SND.

There have been few reports on the alteration of D2 receptors in SND. Brooks et al found a mild diffuse loss of striatal D2 sites in 10 patients with SND using [11C]raclopride and PET. We previously investigated the striatal D2 receptors using PET and [11C]N-methylspiperone, and found that there is a marked loss of striatal D2 receptors, especially in the posterior putamen in SND patients. The present study demonstrated that the distribution of the loss of D1 receptors was similar to the pattern of D2 receptor

**Figure 4** Scattergram showing individual ratios of [11C]SCH23390 uptake in the caudate to that in the occipital cortex, the anterior putamen to that in the occipital cortex, and the posterior putamen to that in the occipital cortex for the normal controls, patients with PD, patients with SND.

**Figure 5** Time course of the ratio of the radioactivity in the posterior putamen to that in the occipital cortex in the control group (n = 6; ○), in the PD group (n = 11; △), and the SND group (n = 5; ■) following [11C]SCH23390 injection. Means and SDs are shown.

**Table 2** [11C]SCH23390 uptake ratios in the control, PD and SND groups

<table>
<thead>
<tr>
<th>Group (n)</th>
<th>Caudate/Cortex Mean (SD)</th>
<th>Ant Putamenum/Cortex Mean (SD)</th>
<th>Post Putamen/Cortex Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls (6)</td>
<td>2.04 (0.20)</td>
<td>2.13 (0.18)</td>
<td>1.94 (0.21)</td>
</tr>
<tr>
<td>PD (11)</td>
<td>1.99 (0.20)</td>
<td>2.07 (0.18)</td>
<td>1.89 (0.19)</td>
</tr>
<tr>
<td>SND (5)</td>
<td>1.82 (0.29)</td>
<td>1.72 (0.38)</td>
<td>1.36 (0.25)*</td>
</tr>
</tbody>
</table>

*p < 0.05 compared with normal control (Bonferroni statistics, n = 3).

*p < 0.01 compared with PD (Bonferroni statistics, n = 3).
loss in SND in our previous study. Based on a pathological study of SND it was proposed that striatal involvement starts dorsally in the posterior two thirds and as it progresses, it spreads ventrally and anteriorly in a dorsolateral manner. The distribution of the loss of dopamine receptors in the present study corresponded to the pattern of striatal involvement in SND. Thus we can conclude that the striatal D1 receptors are located on the striatal neurons which degenerate in SND. It has been reported that striatal D1 receptors are not modified in progressive supranuclear palsy (PSP) patients despite the loss of striatal D2 receptors. The substratification of striatal neurons affected must differ between SND and PSP.

Although the precise functional roles of D1 receptors remain unknown, it has been postulated that D1 receptor activation is required for postsynaptic expression of D2 agonist effects. Therefore, the inefficiency of levodopa in SND might be due to the loss of striatal D1 receptors as well as to the loss of striatal D2 receptors.

It is difficult to diagnose SND with certainty, especially when SND is not associated with pontocerebellar atrophy. MRI may disclose the abnormal hypointensity in the putamen, but only half of the present SND patients showed this abnormality. The width of the pars compacta signal was narrow in the SND patients as well as in the PD patients in this study. These results suggest that it is not possible to differentiate all SND patients from PD patients by MRI.

PET shows a uniform decrease of [18F]fluorodopa uptake in the striatum in multiple system atrophy (MSA) patients, whereas a prominent decrease of [18F] fluorodopa in the putamen with relative sparing of caudate function has been observed by PET in PD patients. But it was also reported that some MSA patients show a pattern similar to that in PD patients; thus this technique could not differentiate all SND patients from PD patients.

PET discloses a considerably decreased glucose utilisation (20-55%) in the striatum of SND patients, whereas glucose utilisation in the striatum of PD patients is normal. Thus PET with [18F]fluorodeoxyglucose (FDG) is a useful tool for the differential diagnosis between SND and PD. However, imaging of dopamine receptors with PET seems superior to PET/FDG for the differential diagnosis of SND and PD, because the radioligand selectively accumulates in the striatum and even the early SND patients (patients 12 and 13) showed a significant decrease of [11C]SCH23390 binding in the posterior putamen. Although further studies are required to determine the selectivity of these abnormal findings in SND using PET, this technique might prove useful for the differential diagnosis of PD and SND.

Desmethylated SCH23390 was kindly supplied by Dr Allen Barnett, Schering Corporation, Bloomfield, New Jersey, USA, and the PET scanner was kindly supplied by Hamamatsu Photonics, KK, Hamamatsu, Japan. The authors wish to thank Dr H Fukuda, Dr M Iyo, Dr H Yonezawa, Mr Itoh, and Dr T Yamashita for their assistance in the PET study, and Dr R Suzuki and Mr K Nemoto for the preparation of [11C]SCH23390. This work was supported by the Japanese Special Coordination Fund for the Promotion of Science and Technology.


Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.

H Shinotoh, O Inoue, K Hiryama, A Aotsuka, M Asahina, T Suhara, T Yamazaki and Y Tateno

*J Neurol Neurosurg Psychiatry* 1993 56: 467-472
doi: 10.1136/jnnp.56.5.467

Updated information and services can be found at:
http://jnnp.bmj.com/content/56/5/467

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/